Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, respectively. It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
It is also indicated as the maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC), which has not progressed with first-line platinum-containing chemotherapy. In the US, avelumab is also indicated to treat locally advanced or metastatic UC with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Avelumab is indicated, in combination with axitinib, for the first-line treatment of advanced renal cell carcinoma (RCC).
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Avelumab Program Rollover Study
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 205
- Registration Number
- NCT03815643
- Locations
- 🇺🇸
Norwalk Hospital - The Whittingham Cancer Center, Norwalk, Connecticut, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 75
- Registration Number
- NCT03812796
- Locations
- 🇬🇧
The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT03800953
- Locations
- 🇨🇳
National Taiwan University Hospital, Taiwan, Taipei, Taiwan
A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- The Christie NHS Foundation Trust
- Registration Number
- NCT03794596
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT03787602
- Locations
- 🇫🇷
CHU de Bordeaux- Hopital Saint-Andre, Bordeaux, France
🇫🇷Hôpital de la Timone. Aix-Marseille Université, Marseille, France
🇫🇷CHU Montpellier, Montpellier, France
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Ashwin Somasundaram
- Target Recruit Count
- 18
- Registration Number
- NCT03783936
- Locations
- 🇺🇸
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 32
- Registration Number
- NCT03774901
- Locations
- 🇫🇷
Antoine THIERY VUILLEMIN, Besançon, France
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Jodi Layton, MD
- Target Recruit Count
- 8
- Registration Number
- NCT03770455
- Locations
- 🇺🇸
Tulane University School of Medicine, New Orleans, Louisiana, United States
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT03747419
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT03747484
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.